Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.

Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ.

J Clin Invest. 2020 Jan 6. pii: 121127. doi: 10.1172/JCI121127. [Epub ahead of print]

2.

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.

Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Szenes V, Park JH, Sauter CS, Heller G, Wang X, Senechal B, O'Reilly RJ, Riviere I, Sadelain M, Brentjens RJ.

Blood. 2019 Dec 26;134(26):2361-2368. doi: 10.1182/blood.2019001641.

PMID:
31650176
3.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R, Tappe W, Soiffer RJ, Grupp SA.

Pediatr Blood Cancer. 2018 Oct;65(10):e27269. doi: 10.1002/pbc.27269. Epub 2018 Jun 6.

4.

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, Lehmann L, Shore T, Ho VT, Bunin N, Iacobelli M, Liang W, Hume R, Tappe W, Soiffer R, Richardson P.

Br J Haematol. 2018 Jun;181(6):816-827. doi: 10.1111/bjh.15267. Epub 2018 May 16.

5.

Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.

Takpradit C, Prockop SE, Kernan NA, Scaradavou A, Curran K, Ruggiero J, Zakak N, O'Reilly RJ, Boulad F.

J Pediatr Hematol Oncol. 2018 May;40(4):e220-e224. doi: 10.1097/MPH.0000000000001106.

6.

Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation.

Davis E, Devlin S, Cooper C, Nhaissi M, Paulson J, Wells D, Scaradavou A, Giralt S, Papadopoulos E, Kernan NA, Byam C, Barker JN.

Biol Blood Marrow Transplant. 2018 May;24(5):1057-1062. doi: 10.1016/j.bbmt.2017.12.791. Epub 2017 Dec 26.

7.

Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.

Giulino-Roth L, O'Donohue T, Chen Z, Trippett TM, Klein E, Kernan NA, Kobos R, Prockop SE, Scaradavou A, Shukla N, Steinherz PG, Moskowitz AJ, Moskowitz CH, Boulad F.

Leuk Lymphoma. 2018 Aug;59(8):1861-1870. doi: 10.1080/10428194.2017.1403601. Epub 2017 Nov 29.

8.

A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.

Spitzer B, Jakubowski AA, Papadopoulos EB, Fuller K, Hilden PD, Young JW, Barker JN, Koehne G, Perales MA, Hsu KC, van den Brink MR, Kernan NA, Prockop SE, Scaradavou A, Castro-Malaspina H, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2088-2095. doi: 10.1016/j.bbmt.2017.07.004. Epub 2017 Jul 12.

9.

Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Getta BM, Roshal M, Zheng J, Park JH, Stein EM, Levine R, Papadopoulos EB, Jakubowski AA, Kernan NA, Steinherz P, O'Reilly RJ, Perales MA, Giralt SA, Tallman MS, Shaffer BC.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1879-1886. doi: 10.1016/j.bbmt.2017.06.026. Epub 2017 Jul 8.

10.

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ.

Br J Haematol. 2017 Jul;178(1):112-118. doi: 10.1111/bjh.14727. Epub 2017 Apr 26.

11.

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Shore T, Iacobelli M, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ; Defibrotide Study Group.

Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8.

12.

Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.

Mehta PA, Davies SM, Leemhuis T, Myers K, Kernan NA, Prockop SE, Scaradavou A, O'Reilly RJ, Williams DA, Lehmann L, Guinan E, Margolis D, Baker KS, Lane A, Boulad F.

Blood. 2017 Apr 20;129(16):2308-2315. doi: 10.1182/blood-2016-09-743112. Epub 2017 Feb 8.

13.

Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, Perales MA.

Leuk Lymphoma. 2017 Aug;58(8):1859-1871. doi: 10.1080/10428194.2016.1265113. Epub 2017 Jan 10.

14.

Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis.

Friedman DN, Hilden P, Moskowitz CS, Suzuki M, Boulad F, Kernan NA, Wolden SL, Oeffinger KC, Sklar CA.

Biol Blood Marrow Transplant. 2017 Mar;23(3):475-482. doi: 10.1016/j.bbmt.2016.12.623. Epub 2016 Dec 28.

15.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM.

Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. Epub 2016 Dec 23.

16.

Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors.

Mussetti A, Kernan NA, Prockop SE, Scaradavou A, Lehrman R, Ruggiero JM, Curran K, Kobos R, O'Reilly R, Boulad F.

Pediatr Hematol Oncol. 2016 Sep;33(6):347-358. Epub 2016 Oct 7.

17.

Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.

Bhatt V, Shune L, Lauer E, Lubin M, Devlin SM, Scaradavou A, Parameswaran R, Perales MA, Ponce DM, Mantha S, Kernan NA, Barker JN.

Bone Marrow Transplant. 2016 Dec;51(12):1579-1583. doi: 10.1038/bmt.2016.228. Epub 2016 Sep 19.

18.

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.

Spitzer B, Perales MA, Kernan NA, Prockop SE, Zabor EC, Webb N, Castro-Malaspina H, Papadopoulos EB, Young JW, Scaradavou A, Kobos R, Giralt SA, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1449-1454. doi: 10.1016/j.bbmt.2016.05.001. Epub 2016 May 13.

19.

Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.

Anur P, Friedman DN, Sklar C, Oeffinger K, Castiel M, Kearney J, Singh B, Prockop SE, Kernan NA, Scaradavou A, Kobos R, Curran K, Ruggiero J, Zakak N, O'Reilly RJ, Boulad F.

Bone Marrow Transplant. 2016 Jul;51(7):938-44. doi: 10.1038/bmt.2016.32. Epub 2016 Mar 21.

20.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ.

Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29.

21.

Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.

Shah GL, Shune L, Purtill D, Devlin S, Lauer E, Lubin M, Bhatt V, McElrath C, Kernan NA, Scaradavou A, Giralt S, Perales MA, Ponce DM, Young JW, Shah M, Papanicolaou G, Barker JN.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2160-2166. doi: 10.1016/j.bbmt.2015.08.010. Epub 2015 Aug 10.

22.

High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, O'Reilly RJ, Papadopoulos EB, Perales MA, Sauter C, Scaradavou A, Tamari R, van den Brink MR, Young JW, Giralt S, Barker JN.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1985-93. doi: 10.1016/j.bbmt.2015.07.029. Epub 2015 Jul 31.

23.

Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.

Harnicar S, Ponce DM, Hilden P, Zheng J, Devlin SM, Lubin M, Pozotrigo M, Mathew S, Adel N, Kernan NA, O'Reilly R, Prockop S, Scaradavou A, Hanash A, Jenq R, van den Brink M, Giralt S, Perales MA, Young JW, Barker JN.

Biol Blood Marrow Transplant. 2015 May;21(5):920-5. doi: 10.1016/j.bbmt.2015.01.024. Epub 2015 Feb 14.

24.

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.

Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, Goldberg JD, Hanash A, Hsu K, Jenq R, Perales MA, Sauter C, van den Brink MR, Young JW, Brentjens R, Kernan NA, Prockop SE, O'Reilly RJ, Scaradavou A, Paczesny S, Barker JN.

Blood. 2015 Jan 1;125(1):199-205. doi: 10.1182/blood-2014-06-584789. Epub 2014 Nov 6.

25.

Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.

Dahi PB, Perales MA, Devlin SM, Olson A, Lubin M, Gonzales AM, Scaradavou A, Kernan NA, O'Reilly RJ, Giralt S, Jakubowski A, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Papanicolaou G, Barker JN.

Leuk Lymphoma. 2015 Jun;56(6):1799-805. doi: 10.3109/10428194.2014.963079. Epub 2014 Oct 21.

26.

Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice.

Purtill D, Smith K, Devlin S, Meagher R, Tonon J, Lubin M, Ponce DM, Giralt S, Kernan NA, Scaradavou A, Stevens CE, Barker JN.

Blood. 2014 Nov 6;124(19):2905-12. doi: 10.1182/blood-2014-03-566216. Epub 2014 Sep 2.

27.

Donor-recipient allele-level HLA matching of unrelated cord blood units reveals high degrees of mismatch and alters graft selection.

Dahi PB, Ponce DM, Devlin S, Evans KL, Lubin M, Gonzales AM, Byam C, Sideroff M, Wells D, Giralt S, Kernan NA, Scaradavou A, Barker JN.

Bone Marrow Transplant. 2014 Sep;49(9):1184-6. doi: 10.1038/bmt.2014.135. Epub 2014 Jul 7.

28.

Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.

Olson AL, Dahi PB, Zheng J, Devlin SM, Lubin M, Gonzales AM, Giralt SA, Perales MA, Papadopoulos EB, Ponce DM, Young JW, Kernan NA, Scaradavou A, O'Reilly RJ, Small TN, Papanicolaou G, Barker JN.

Biol Blood Marrow Transplant. 2014 Jun;20(6):787-93. doi: 10.1016/j.bbmt.2014.02.010. Epub 2014 Feb 16.

29.

A 16-year-old transplant patient with amnesia, insomnia, and visual hallucinations.

Graber JJ, Kernan NA, Khakoo Y.

Neurol Clin Pract. 2014 Feb;4(1):88-90. doi: 10.1212/CPJ.0b013e3182a9c641. No abstract available.

30.

Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies.

Dahi PB, Barone J, Devlin SM, Byam C, Lubin M, Ponce DM, Giralt S, Kernan NA, Scaradavou A, Hsu SH, Barker JN.

Biol Blood Marrow Transplant. 2014 May;20(5):735-9. doi: 10.1016/j.bbmt.2014.01.017. Epub 2014 Jan 23.

31.

"No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment.

Dahi PB, Ponce DM, Devlin S, Evans KL, Lubin MN, Gonzales AM, Tonon J, Meagher R, Giralt S, Kernan NA, Scaradavou A, Barker JN.

Biol Blood Marrow Transplant. 2014 Apr;20(4):490-4. doi: 10.1016/j.bbmt.2013.12.561. Epub 2013 Dec 18.

32.

Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.

Giulino-Roth L, Ricafort R, Kernan NA, Small TN, Trippett TM, Steinherz PG, Prockop SE, Scaradavou A, Chiu M, O'Reilly RJ, Boulad F.

Pediatr Blood Cancer. 2013 Dec;60(12):2018-24. doi: 10.1002/pbc.24722. Epub 2013 Aug 30.

PMID:
24038967
33.

Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.

Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB.

Biol Blood Marrow Transplant. 2013 Jun;19(6):898-903. doi: 10.1016/j.bbmt.2013.02.018. Epub 2013 Mar 1.

34.

Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD, Hanash AM, Jakubowski A, Jenq R, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, O'Reilly RJ, Prockop S, Small TN, Scaradavou A, Kernan NA, Stevens CE, Barker JN.

Biol Blood Marrow Transplant. 2013 Jun;19(6):904-11. doi: 10.1016/j.bbmt.2013.02.008. Epub 2013 Feb 14.

35.

A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA, Scaradavou A, Giralt S, Goldberg JD, Koehne G, Perales MA, Young JW, Castro-Malaspina H, Jakubowski A, Papadopoulos EB, Barker JN.

Biol Blood Marrow Transplant. 2013 May;19(5):799-803. doi: 10.1016/j.bbmt.2013.02.007. Epub 2013 Feb 14.

36.

Drug safety evaluation of defibrotide.

Richardson PG, Corbacioglu S, Ho VT, Kernan NA, Lehmann L, Maguire C, Maglio M, Hoyle M, Sardella M, Giralt S, Holler E, Carreras E, Niederwieser D, Soiffer R.

Expert Opin Drug Saf. 2013 Jan;12(1):123-36. doi: 10.1517/14740338.2012.749855. Epub 2012 Dec 10. Review.

PMID:
23228043
37.

T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.

Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MR, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Prockop SE, Yahalom J, Heller G, Perales MA.

Biol Blood Marrow Transplant. 2013 Feb;19(2):208-13. doi: 10.1016/j.bbmt.2012.09.003. Epub 2012 Sep 13.

38.

Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.

Friedman DN, Sklar CA, Oeffinger KC, Kernan NA, Khakoo Y, Marr BP, Wolden SL, Abramson DH, Dunkel IJ.

Pediatr Blood Cancer. 2013 Apr;60(4):694-9. doi: 10.1002/pbc.24280. Epub 2012 Aug 21.

PMID:
22911631
39.

The use of back-up units to enhance the safety of unrelated donor cord blood transplantation.

Ponce DM, Lubin M, Gonzales AM, Byam C, Wells D, Ferrante R, Heller G, Giralt S, Papadopoulos EB, Kernan NA, Scaradavou A, Barker JN.

Biol Blood Marrow Transplant. 2012 Apr;18(4):648-51. doi: 10.1016/j.bbmt.2011.12.588. Epub 2012 Jan 11.

40.

Paroxysmal nocturnal hemoglobinuria in pediatric patients.

Curran KJ, Kernan NA, Prockop SE, Scaradavou A, Small TN, Kobos R, Castro-Malaspina H, Araten D, DiMichele D, O'Reilly RJ, Boulad F.

Pediatr Blood Cancer. 2012 Sep;59(3):525-9. doi: 10.1002/pbc.23410. Epub 2011 Dec 6.

PMID:
22147651
41.

Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.

Avery S, Voss MH, Gonzales AM, Lubin M, Castro-Malaspina H, Giralt S, Kernan NA, Scaradavou A, Hedvat CV, Stevens CE, Barker JN.

Bone Marrow Transplant. 2012 Aug;47(8):1056-60. doi: 10.1038/bmt.2011.236. Epub 2011 Dec 5.

42.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O'Reilly RJ.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

43.

Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.

Kobos R, Steinherz PG, Kernan NA, Prockop SE, Scaradavou A, Small TN, Shukla N, Khalaf R, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2012 Mar;18(3):473-80. doi: 10.1016/j.bbmt.2011.11.009. Epub 2011 Nov 10.

44.

Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.

Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN.

Biol Blood Marrow Transplant. 2012 Jan;18(1):145-9. doi: 10.1016/j.bbmt.2011.07.027. Epub 2011 Aug 4.

45.

T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia.

Tarek N, Kernan NA, Prockop SE, Scaradavou A, Small TN, O'Reilly RJ, Boulad F.

Bone Marrow Transplant. 2012 May;47(5):744-6. doi: 10.1038/bmt.2011.142. Epub 2011 Jul 25. No abstract available.

PMID:
21785471
46.

Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J, Small TN.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1708-13. doi: 10.1016/j.bbmt.2011.05.006. Epub 2011 May 23.

47.

Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.

Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne G, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, Kernan NA, Kobos R, Prockop S, Scaradavou A, Small T, O'Reilly RJ, Barker JN.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1316-26. doi: 10.1016/j.bbmt.2011.01.006. Epub 2011 Jan 11.

48.

T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.

Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, Hsu KC, Perales MA, Papanicolaou G, van den Brink MR, O'Reilly RJ, Young JW, Papadopoulos EB.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1335-42. doi: 10.1016/j.bbmt.2011.01.005. Epub 2011 Jan 11.

49.

Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.

Avery S, Shi W, Lubin M, Gonzales AM, Heller G, Castro-Malaspina H, Giralt S, Kernan NA, Scaradavou A, Barker JN.

Blood. 2011 Mar 24;117(12):3277-85; quiz 3478. doi: 10.1182/blood-2010-08-300491. Epub 2010 Dec 13.

50.

Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities.

Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, Wells DS, Heller G, Papadopoulos EB, Scaradavou A, Young JW, van den Brink MR.

Biol Blood Marrow Transplant. 2010 Nov;16(11):1541-8. doi: 10.1016/j.bbmt.2010.08.011. Epub 2010 Aug 25.

Supplemental Content

Loading ...
Support Center